CV Bio

DNX-2401

Investment Opportunity

Differentiated Intratumoral Oncolytic Adenovirus with Dual Oncolytic + Immune-Stimulatory Activity

- Engineered adenovirus: 24 bp E1A deletion (tumor-selective replication) + RGD-4C motif for integrin targeting
- Intratumoral delivery limits systemic exposure
- Strong clinical signals:
  - Pediatric Ph.1 monotherapy in DIPG: median OS = 17.8 months (durable responses vs historical SOC); ORR 25% associated with longer survival
  - Adult Ph. 1 monotherapy in recurrent glioblastoma multiforme: median OS = 9.5 months
- Safety profile: low systemic toxicity and manageable intratumoral administration in pediatrics and adults
- Regulatory tailwinds: FDA Fast Track, orphan and rare pediatric disease designations; priority review voucher eligibility for DIPG pathway
- Uniquely positioned as potential first-line monotherapy in pediatric DMG



Clinical Partners

Princes Máxima Centrum kinderoncologie
Universidad de Navarra
Children's Hospital of Philadelphia
Seattle Children's HOSPITAL • RESEARCH • FOUNDATION

FDA DIPG Rare Pediatric Designation

FDA DIPG Fast Track

FDA Orphan Drug & Fast Track Designation

EU Orphan Drug Designation

Upcoming Milestones

Q1'26
Initiate Ph. 1/2 PNOC DMG Trial

Q3'26
Repeat dose feasibility data

1H'27
FDA meeting to discuss accelerated approval with expansion

2026

PNOC Ph. 1/2 Pediatric Upfront DMG Trial (Cohort 6)

Ongoing EU Ph. 2 Pediatric Recurrent Brain Cancer Trial

Q2'26
New tumor types initial safety data

Dose escalation safety data

Q4'26
Initiate expansion phase

2027

Proposed Convertible Note Offering

CV Bio is raising an $8.0M Convertible Bridge Note to fund operations through a potential strategic transaction within 12–18 months

CV Bio presents a compelling investment opportunity in DNX-2401, a clinically validated, intratumoral oncolytic adenovirus immunotherapy uniquely positioned to address high-unmet-need pediatric brain cancers — including Diffuse Intrinsic Pontine Glioma (DIPG), Diffuse Midline Glioma (DMG), and recurrent pediatric high-grade gliomas. To advance this program, CV Bio is raising an $8,000,000 Convertible Bridge Note to fund operations through a potential strategic transaction within the next 12 to 18 months.

Attractive profile driving strategic interest:

- Two active international pediatric brain tumor trials underway
- Clear pathway toward accelerated approval
- FDA Priority Review Voucher eligible
- Robust Ph. 1 clinical data in DIPG and currently advancing across international Ph. 1/2 and Ph. 2 studies evaluating optimized repeat-dosing regimens and expanded pediatric indications

Convertible Bridge Note Terms

1. *Up to $8.0M aggregate principal amount*
2. *Accrues interest at 8.0% per annum, with a 20% discount (mandatory conversion at 80%) of the purchase price in an M&A transaction*
3. *Matures in 3 years. If not converted sooner, it converts at maturity into Series A shares at $1.00 per share*

Please direct all inquiries regarding this transaction to:

Harry Bushong
President
hbushong@convergence-ventures.com